PPP-001 is under clinical development by Tetra Bio-Pharma and currently in Phase III for Cancer Pain. According to GlobalData, Phase III drugs for Cancer Pain does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the PPP-001 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PPP-001 overview
PPP-001 is under development for the treatment of advanced cancer pain, fibromyalgia and complex regional pain syndrome (CRPS). The drug candidate is a fixed-dose combination of cannabidiol and dronabinol. It is a smokable marijuana candidate formulated as pellet and administered by inhalational route. It acts by targeting cannabinoid receptor1 (CB1) and cannabinoid receptor 2 (CB2). It was also under development for cancer cachexia.
Tetra Bio-Pharma overview
Tetra Bio-Pharma discovers and develops cannabinoid-derived drugs and natural health products. The company’s pipeline product’s therapeutic areas include pain, inflammation, ophthalmology and oncology. Its pain and chemo-induced nausea and vomiting products include QIXLEEF and CAUMZ, REDUVO and ADVERSA. Tetra Bio-Pharma immunomodulator products are ARDS003 and PPP003. The company works in partnership with Altasciences, Cellvera, DanCann Pharma A/S, The Alternavida Group, Altus Formulation, Azevedos Group, The George Mason University National Center for Biodefense and Infectious Diseases (NCBID), Kamada Ltd and Targeted Pharmaceuticals Inc, among others. It operates in Canada, Australia and Malta. Tetra Bio-Pharma is headquartered in Orleans, Ontario, Canada.
For a complete picture of PPP-001’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
